Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase.J Mol Biol. 1975; 94: 441-448
- ACMG clinical laboratory standards for next-generation sequencing.Genet Med. 2013; 15: 733-747
- Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.J Mol Diagn. 2010; 12: 425-432
- EGFR testing in advanced non–small-cell lung cancer, a mini-review.Clinical Lung Cancer. 2016; 17: 483-492
- Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.Nat Rev Clin Oncol. 2018; 15: 639-650
- Prospective enterprise-level molecular genotyping of a cohort of cancer patients.J Mol Diagn. 2014; 16: 660-672
- A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.J Mol Diagn. 2011; 13: 74-84
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2021; 71: 209-249
- Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer.JCO Clin Cancer Inform. 2019; 3: 1-10
- Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].J Clin Oncol. 2003; 21: 2237-2246
- Erlotinib in cancer treatment.Ann Oncol. 2007; 18: vi35-vi41
- Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib.N Engl J Med. 2004; 350: 2129-2139
- EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.Science. 2004; 304: 1497-1500
- Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.Nature. 2007; 448: 561-566
- First-line crizotinib versus chemotherapy in ALK-positive lung cancer.N Engl J Med. 2014; 371: 2167-2177
- Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.J Mol Diagn. 2013; 15: 415-453
- Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations.Cancers (Basel). 2021; 13https://doi.org/10.3390/cancers13040804
- Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.Ann Oncol. 2019; 30: 1121-1126
- Capmatinib for the treatment of non-small cell lung cancer.Expert Rev Anticancer Ther. 2019; 19: 659-671
- Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children.N Engl J Med. 2018; 378: 731-739
- EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.Mol Cancer Ther. 2013; 12: 220-229
- MET exon 14 skipping mutations in non-small-cell lung cancer: an overview of biology, clinical outcomes, and testing considerations.JCO Precis Oncol. 2021; https://doi.org/10.1200/PO.20.00516
- High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden.Clin Cancer Res. 2019; 25: 4712-4722
- Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.J Mol Diagn. 2018; 20: 129-159
- NCCN guidelines insights: non-small cell lung cancer, version 2.2021.J Natl Compr Canc Netw. 2021; 19: 254-266
Network NCC. Non-small cell lung cancer. Accessed January 1, 2022.
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.Ann Oncol. 2020; 31: 1491-1505
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.Br J Cancer. 2019; 121: 725-737
- Understanding and targeting resistance mechanisms in NSCLC.Nat Rev Cancer. 2017; 17: 637-658
- Biomarker-driven targeted therapies in solid tumor malignancies.J Hematol Oncol Pharm. 2021; 11: 84-91
- Challenges in the clinical implementation of precision medicine companion diagnostics.Expert Rev Mol Diagn. 2020; 20: 593-599
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.Ann Oncol. 2019; 30: 44-56
- Detection of mismatch repair deficiency and microsatellite instability in colorectal adenocarcinoma by targeted next-generation sequencing.J Mol Diagn. 2017; 19: 84-91
- Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data.JCO Precis Oncol. 2017; https://doi.org/10.1200/PO.17.00084
- Identifying optimal loci for the molecular diagnosis of microsatellite instability.Clin Chem. 2020; 66: 1310-1318
- Deciphering signatures of mutational processes operative in human cancer.Cell Rep. 2013; 3: 246-259
- Signatures of mutational processes in human cancer.Nature. 2013; 500: 415-421
- Performance characteristics of mutational signature analysis in targeted panel sequencing.Arch Pathol Lab Med. 2021; 145: 1424-1431
- Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project.Ann Oncol. 2021; 32: 1626-1636
- Is the $1000 genome as near as we think? A cost analysis of next-generation sequencing.Clin Chem. 2016; 62: 1458-1464
- Molecular Pathology economics 101: an overview of molecular diagnostics coding, coverage, and reimbursement: a report of the association for molecular Pathology.J Mol Diagn. 2020; 22: 975-993
- Clinical utilization, utility, and reimbursement for expanded genomic panel testing in adult oncology.JCO Precision Oncol. 2020; : 1038-1048
- Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision analytic model.JCO Precision Oncol. 2019; 3: 1-9
- The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations—the Lung Cancer Mutation Consortium (LCMC2).Clin Cancer Res. 2018; 24: 1038-1047
- Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.Nat Commun. 2021; 12: 6450
- Integrative profiling of T790M-negative EGFR-mutated NSCLC reveals pervasive lineage transition and therapeutic opportunities.Clin Cancer Res. 2021; 27: 5939-5950
- STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma.Cancer Discov. 2018; 8: 822-835
- Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status.J Thorac Oncol. 2021; https://doi.org/10.1016/j.jtho.2021.10.013
- The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer.Clin Cancer Res. 2020; 26: 5701-5708
- SMARCA4 and other SWItch/sucrose nonfermentable family genomic alterations in NSCLC: clinicopathologic characteristics and outcomes to immune checkpoint inhibition.J Thorac Oncol. 2021; 16: 1176-1187
- Molecular-based precision oncology clinical decision making augmented by artificial intelligence.Emerg Top Life Sci. 2021; 5: 757-764
- Integrated analysis of whole genome and epigenome data using machine learning technology: toward the establishment of precision oncology.Front Oncol. 2021; 11: 666937https://doi.org/10.3389/fonc.2021.666937
- Studies on the in vitro biological N-oxidation of trimethoprim.Eur J Drug Metab Pharmacokinet. 1987; 12: 245-251
- Utility of homologous recombination deficiency biomarkers across cancer types.JCO Precis Oncol. 2021; https://doi.org/10.1200/PO.21.00141
- Clinical assays for assessment of homologous recombination DNA repair deficiency.Gynecol Oncol. 2020; 159: 887-898
- Evaluation of a hybrid capture–based pan-cancer panel for analysis of treatment stratifying oncogenic aberrations and processes.J Mol Diagn. 2020; 22: 757-769
Article info
Publication history
Published online: August 22, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
